(secondQuint)Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease.

 This is a Phase II, multicenter, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the efficacy and safety of KPI-121 ophthalmic suspension versus vehicle in subjects with signs and symptoms of inflammatory meibomian gland disease.

 The product will be studied over 28 days, with 1-2 drops instilled in each eye four times daily (QID).

.

 Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease@highlight

The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to vehicle (placebo) in subjects with signs and symptoms of inflammatory meibomian gland disease.

